Back to Peptide Deep Dives
Peptide Deep Dives•••11 min read

What Is Melanotan 2 (MT-2)?

What Melanotan 2 is, what its small 1990s human studies found, the melanoma, mole and priapism case reports, and why it has no approved path in 2026.

PeptIQ Team
Peptide Research & Education
Melanotan 2 (MT-2): Risks, Evidence & FDA Status

PeptIQ app

Log your Melanotan protocol in PeptIQ

Turn this Melanotan guide into a living protocol — doses, vials, and history in one place.

Track MelanotanOpen web app

iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

TL;DR

Melanotan 2 (MT-2, Melanotan II) is a synthetic, lab-made version of alpha-melanocyte-stimulating hormone, the body's own signal for darkening skin. It was designed at the University of Arizona as a sunless tan, and it is sold online today as a "tanning peptide," nasal spray or research chemical.

  • It does tan human skin. A 1996 pilot study in three healthy men measured darker pigmentation on the face, upper body and buttocks after a short course of injections.
  • It is not selective. In the same study, and in two small erectile dysfunction trials that followed, it caused spontaneous erections, nausea, yawning and stretching, and reduced appetite. About one in eight men in the erection trials had severe nausea.
  • Its relatives were developed into approved drugs; MT-2 never was. Melanotan I became afamelanotide (Scenesse) for a rare light-sensitivity disorder. An MT-2 analogue became bremelanotide (Vyleesi) for low sexual desire. Both were approved in 2019, with labels, dose limits and safety monitoring. MT-2 itself never finished development.
  • The safety record is case reports, and it is consistent. Dermatologists have published new and darkening moles appearing within days, several melanomas, priapism needing emergency treatment, rhabdomyolysis with kidney injury, a brain swelling syndrome and a kidney infarction in people using it.
  • 2026 status: no FDA-approved product. FDA publishes an explicit safety-risk summary for compounding with it, and its nomination for the 503A compounding list was withdrawn. It is not in the October 2026 HHS peptide policy, and FDA lists "Melanotan (I and II)" on an import alert. The only registered trial is a phase 2 vitiligo study in China that is still recruiting.

This PeptIQ.io guide was rewritten on November 19, 2026 from PubMed, ClinicalTrials.gov, FDA compounding and import records and Drugs@FDA. It replaces an older version of this page and contains no dosing information.

Talk to a licensed clinician before using anything sold as Melanotan 2, especially if you have many moles, a personal or family history of melanoma, or heart or kidney disease.

What Is Melanotan 2?

Your skin color is controlled in part by a hormone called alpha-melanocyte-stimulating hormone (alpha-MSH). It binds a receptor on pigment cells, MC1R, and tells them to make more of the darker form of melanin. Sunlight raises it, which is part of how a tan develops.

In the 1980s and 1990s a University of Arizona group led by Mac Hadley, Victor Hruby and Robert Dorr built stronger, longer-lasting versions of that hormone. The idea was protective: a tan without the ultraviolet damage. Two analogues came out of the program:

  • Melanotan I, a linear peptide that stayed relatively focused on pigmentation.
  • Melanotan II, a smaller cyclic seven-amino-acid peptide that was far more potent, and far less selective.

Alpha-MSH belongs to a family of hormones called melanocortins, and melanocortin receptors are not only in skin. Related receptors in the brain help control sexual arousal, appetite and blood pressure. A drug that hits all of them at once does more than tan you. That turned out to be the defining fact of MT-2.

PeptIQ.io / Melanotan 2 / 01

Its relatives got approved. It didn’t.

One University of Arizona program set out to make a safer tan. The more targeted molecules became regulated drugs. The unselective original is the one sold as a tanning peptide.

The parent signal

Alpha-MSH, the body’s own “make pigment” hormone

Its receptor family is not only in skin. Related receptors in the brain help control sexual response, appetite and blood pressure.

Three analogues, three outcomes

  • Melanotan I

    Linear analogue, focused on pigment

    Became afamelanotide (Scenesse) for erythropoietic protoporphyria, a rare light-sensitivity disorder.

    FDA approved · Oct 2019

  • PT-141

    Analogue of Melanotan II

    Became bremelanotide (Vyleesi) for low sexual desire in premenopausal women, with blood pressure limits on its label.

    FDA approved · Jun 2019

  • Melanotan II

    Small cyclic analogue, potent and unselective

    Tans skin, but also triggers erections, nausea and appetite changes. Development stopped; sold online instead.

    Never approved

A separate melanocortin drug, setmelanotide (Imcivree, approved Nov 2020), treats specific genetic forms of obesity. Its label lists skin darkening and new moles.

Evidence, not marketing.Nov 2026
Sources: Hadley & Dorr, Peptides 2006 (PubMed 16412534); Hadley, Peptides 2005 (PubMed 15996790); Drugs@FDA records for Scenesse (NDA 210797), Vyleesi (NDA 210557) and Imcivree (NDA 213793). Simplified for education; not treatment advice.

Hadley later wrote that MT-2's effect on sexual function was "discovered accidentally while studying the effects of the peptide and related analogs on human skin pigmentation." The program split. Melanotan I went on to become afamelanotide, approved by FDA as Scenesse on October 8, 2019, for people with erythropoietic protoporphyria, a rare genetic disorder that makes sunlight painful. An MT-2 analogue, PT-141, became bremelanotide, approved as Vyleesi on June 21, 2019, for low sexual desire in premenopausal women. A third melanocortin drug, setmelanotide (Imcivree), was approved on November 25, 2020, for specific genetic causes of obesity.

Each of those drugs is more targeted than MT-2, was tested in controlled trials and carries a label that warns about skin darkening, moles or blood pressure. MT-2 is what is left over: the unselective original, sold without any of that.

What the Evidence Actually Shows

The human research on MT-2 is old, small and short. Here is all of it that matters, by question.

PeptIQ.io / Melanotan 2 / 02

Thirty years on, the trials are still tiny.

Every controlled human study of Melanotan 2 fits in one table. The effect people buy it for has the thinnest support of all.

  1. Erections in men with ED

    Two placebo-controlled crossover trials, 20 men in total. Erections in 17 of 20; severe nausea in 12.9%.

    Shown, small
  2. Tanning in people

    One pilot study: three healthy men, two weeks. Two had measurable darkening. The larger tanning trials used Melanotan I.

    Pilot only
  3. Vitiligo repigmentation

    One phase 2 placebo-controlled trial with light therapy, recruiting in China (NCT07437560). No results yet.

    Under study
  4. Appetite or weight loss

    Rodent studies and a side effect noted in the ED trials. No human weight study.

    Untested
  5. Skin cancer protection or long-term safety

    The original goal of the program. No human trial has tested either. The case reports point the other way.

    Untested
Evidence, not marketing.Nov 2026
Sources: Dorr et al., Life Sci 1996 (PubMed 8637402); Wessells et al., J Urol 1998 (PubMed 9679884), Urology 2000 (PubMed 11018622), Int J Impot Res 2000 (PubMed 11035391); Dorr et al., Arch Dermatol 2004 (PubMed 15262693); ClinicalTrials.gov NCT07437560, searched Nov 19, 2026.

Does it tan people?

Yes, in a pilot sense. The 1996 phase 1 study gave MT-2 or saline on alternating days to three healthy men. Two of them had measurable darkening of the face, upper body and buttocks a week after the injections ended. The same study recorded mild nausea at most exposures, somnolence and fatigue in one man at the highest exposure, and a "stretching and yawning complex" that came with intermittent spontaneous erections for one to five hours afterward.

That is the entire published controlled human tanning evidence for MT-2: three people, two weeks. The larger tanning trials from the Arizona group used Melanotan I, not MT-2. In those studies, MT-1 combined with sunlight produced a deeper tan that lasted longer than sunlight alone, and the main side effects were nausea and facial flushing. That is the molecule that became an approved drug.

Does it cause erections?

Yes, and this is the best-studied effect. Two double-blind, placebo-controlled crossover trials at the University of Arizona enrolled 20 men with erectile dysfunction in total: ten with psychogenic and ten with organic causes. MT-2 produced erections without sexual stimulation in 17 of 20 men, and men reported more sexual desire after MT-2 than after placebo. Nausea and yawning were the common side effects, and 12.9% of the men had severe nausea. A 2026 systematic review of peptides for male sexual function concluded that melanocortin agonists have the most consistent erectile evidence of any peptide class, but that the studies are small and short.

Those findings did not lead to an MT-2 approval. They led to bremelanotide, a related analogue developed for a narrower purpose.

Does it help with appetite or weight?

Not in any human study. The appetite and weight claims come from rodent research and from the reduced appetite noted as a side effect in the erection trials. The melanocortin drug that is actually approved for weight, setmelanotide, works only in people with specific genetic defects in this pathway, and its label lists skin darkening and new moles among its effects. See our setmelanotide guide.

Does it protect against skin cancer?

That was the original hope. There is no human evidence that MT-2 does, and the case reports below point the other way for people who already have many or atypical moles.

Is anyone studying it now?

One registered trial, found by searching ClinicalTrials.gov on November 19, 2026: NCT07437560, a randomized, placebo-controlled phase 2 study of MT-2 added to narrowband UV-B light therapy for stable vitiligo, sponsored by Hudson Biotech. It is recruiting in China, with an estimated 60 participants and primary completion estimated for February 2027. It is a real medical question — whether the pigment signal can help repigment white patches — and it says nothing yet about cosmetic tanning.

The Safety Record: What the Case Reports Show

Case reports cannot tell you how often something happens. They tell you what has happened, to whom and how quickly. For an unapproved drug with no long-term trial, they are the safety record, and FDA cites them directly.

PeptIQ.io / Melanotan 2 / 03

What the case reports keep finding.

Case reports cannot tell you how common a harm is. They show what has happened, and FDA now quotes them in its own safety notice.

  • Moles

    New moles erupting in crops and existing moles darkening, in one report within 24 hours of a single injection.

  • Melanoma

    Four cases counted by a 2017 review, then a mouth melanoma after nasal spray (2025) and five melanomas in situ in one patient (2026).

  • Priapism

    Prolonged erections reported in 2013, 2019 and 2021. The 2019 case needed hospital drainage; the 2021 case needed surgery.

  • Body-wide toxicity

    Racing heart and rhabdomyolysis with kidney injury (2012), a brain-swelling syndrome (2013), a kidney infarction (2020).

FDA, in its own words

“Melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.”

What was in the vials

Online products tested at roughly 43–88% of the labeled amount, with unidentified impurities in two of three shops.

Evidence, not marketing.Nov 2026
Sources: Cardones & Grichnik 2009 (PubMed 19380666); Schulze et al. 2014 (PubMed 24334249); Habbema et al. 2017 (PubMed 28266027); Yassin Alsabbagh et al. 2025 (PubMed 40210573); Vadner & Smith 2026 (PubMed 42328529); Devlin et al. 2013 (PubMed 23537392); Dreyer et al. 2019 (PubMed 30796078); Mallory et al. 2021 (PubMed 33460908); Nelson et al. 2012 (PubMed 23121206); Kaski et al. 2013 (PubMed 23648958); Peters et al. 2020 (PubMed 31953620); Breindahl et al. 2015 (PubMed 24771717); FDA significant safety risks page, read Nov 19, 2026.

Moles that change fast. The most frequent finding is melanocytic: new moles erupting in crops, and existing moles darkening or changing shape. A 2009 report described a man with prior melanoma and atypical moles who developed crops of new moles with atypical features after using a synthetic alpha-MSH; they lightened after he stopped. A 2014 German report documented new moles and darkening of existing moles 24 hours after a single injection. Similar cases have been published in Irish, Spanish, Danish and Swedish medical journals.

Melanoma. A 2017 dermatology review counted four published cases of melanoma arising from existing moles during or shortly after melanotan use, while noting that a causal link has not been proven. Later reports include a 20-year-old Danish woman who had used MT-2 alongside tanning beds, a 22-year-old UK patient with a mucosal melanoma in the upper jaw after using an MT-2 nasal spray, and a 2026 report of five separate melanomas in situ in one patient with tanning-bed use, melanotan exposure and anabolic hormone use. Sunbeds are a confounder in several of these, and that is part of the point: people who use MT-2 usually use it to tan harder, not instead of tanning.

Priapism. Published cases from 2013, 2019 and 2021 describe prolonged erections after injecting melanotan. The 2019 patient needed blood drained from the penis in hospital and had not regained erectile function four weeks later; the 2021 patient needed surgical decompression.

Whole-body toxicity. A 2012 case from a US poison center described a man with racing heart, sweating, tremor and agitation after injecting MT-2, who went on to develop severe rhabdomyolysis (muscle breakdown) and kidney injury requiring intensive care. The product was confirmed as MT-2 by mass spectrometry. A 2020 Swedish case and literature review linked MT-2 to a kidney infarction. A 2013 Annals of Internal Medicine letter described posterior reversible encephalopathy syndrome, a brain-swelling condition usually associated with sudden rises in blood pressure. An October 2026 emergency-medicine report described tachycardia and rhabdomyolysis after a "melanotan" injection — where testing found an undisclosed synthetic cannabinoid as well.

What is in the vial. A 2015 laboratory analysis of MT-2 bought from three online shops found every vial contained less than labeled — between about 43% and 88% of the stated amount — and two of the three shops' products carried roughly 4–6% unidentified impurities. The 2026 cannabinoid case is a reminder that the label may not describe the contents at all.

Dermatologists have also written about melanotan use being promoted on social media, and about tanning-driven use overlapping with body dysmorphic concerns. Those are worth naming honestly if they apply.

Regulatory Status in 2026

Never FDA approved. There is no FDA-approved Melanotan II product for any use. The approved melanocortin drugs are different molecules: Scenesse (afamelanotide, NDA 210797), Vyleesi (bremelanotide, NDA 210557) and Imcivree (setmelanotide, NDA 213793).

FDA's compounding safety notice. FDA's page on bulk substances that may present significant safety risks (content current as of April 22, 2026) lists Melanotan II among substances whose 503A nominations were withdrawn after being placed in the safety-risk category. FDA's summary reads: compounded drugs containing Melanotan II "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism." A withdrawn nomination means it is not on the 503A bulks list and is not covered by FDA's interim compounding policy.

Not in the October 2026 HHS policy. The enforcement-discretion policy published in the Federal Register on October 30, 2026 covers six peptides in its Appendix A. Melanotan II is not one of them. Our guide to that policy explains what it does and does not allow.

Flagged at the border. FDA Import Alert 66-41, covering unapproved new drugs, lists "Melanotan (I and II)" with the note that the product "is imported as non-human research purposes only and then the unapproved new drug is sold on internet," and separately lists Melanotan II from a Chinese supplier.

Outside the US. A 2017 review in the International Journal of Dermatology notes that multiple national health agencies have issued safety warnings about melanotan I and II, and the 2025 UK case report describes its sale as illegal in the UK and many other countries.

So the plain answer to "is Melanotan 2 legal?" in the US: there is no approved product, no lawful compounding route under current FDA policy, and products marketed "for research" are not legal drugs for people.

Safety Questions to Raise With a Clinician

None of these have a dosing answer. They are the questions the published record says matter.

  • How many moles do I have, and has anyone mapped them? People with many or atypical moles, prior melanoma or a family history are exactly the group the case reports describe. A dermatologist can photograph and check them.
  • Would I be using this to tan more, not less? In several melanoma reports, MT-2 was used alongside sunbeds.
  • What about my blood pressure, heart and kidneys? Published harms include sympathetic overdrive, rhabdomyolysis, a kidney infarction and a blood-pressure-linked brain syndrome. The approved MT-2 analogue, Vyleesi, carries blood pressure limits on its label for a reason.
  • What would I do if I got an erection that would not go away? Priapism is an emergency; the 2019 and 2021 cases needed hospital procedures.
  • Is this a medical problem with an approved option? For low sexual desire, see our PT-141 / bremelanotide guide. For light sensitivity disorders, a specialist can discuss afamelanotide. For vitiligo, light therapy and other treatments are established.
  • What is actually in the product? Testing has found under-filled vials, impurities and an undisclosed drug. Our certificate of analysis guide explains what a lab report can and cannot prove.

For background, the Melanotan II brand site in the Meds.you portfolio states that MT-2 has never received FDA approval and that there is currently no legal pathway for a US pharmacy to compound it; it offers an email notice if that changes rather than a product.

How PeptIQ.io Helps

PeptIQ.io does not sell peptides. Our Peptide Claim Auditor takes a link to an Instagram, TikTok, X or Reddit post and checks its claims against published research — useful for "tanning peptide" posts, where the pigmentation is real but the safety claims are not. The Melanotan II compound profile tracks its regulatory status, and our guide to vetting a peptide source covers supply-chain questions. If you are working with a clinician, the PeptIQ app keeps medications, symptoms and photos on one timeline, and PeptIQ AI answers questions against your own log instead of a forum thread.

Talk to a Licensed Clinician

Talk to a licensed clinician before using anything sold as Melanotan 2. It is an unapproved drug with tiny, decades-old human studies, an FDA safety notice citing melanoma, brain, toxic and priapism case reports, and a product supply that has tested under-filled and contaminated. If you have already used it, tell your doctor and ask for a full skin check, especially if any mole has appeared, darkened or changed since.

Frequently Asked Questions

Q: What is Melanotan 2?

A: Melanotan 2 (MT-2 or Melanotan II) is a synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone, developed at the University of Arizona in the 1990s as a sunless tanning agent. It activates several melanocortin receptors, so in addition to darkening skin it causes erections, nausea and appetite changes. It has never been approved as a drug.

Q: Is Melanotan 2 FDA approved?

A: No. There is no FDA-approved Melanotan II product. FDA publishes a compounding safety summary for it citing immunogenicity risk and case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism, and its nomination for the 503A compounding list was withdrawn. It is not covered by the October 2026 HHS peptide compounding policy.

Q: Does Melanotan 2 cause skin cancer?

A: That has not been proven. What has been published is a series of case reports: new and rapidly darkening moles, sometimes within a day of use, and several melanomas in people who had used melanotan, often alongside sunbeds. A 2017 review counted four melanoma cases and noted that a causal link is not established. Because a large trial has never been run, the true risk is unknown.

Q: What are the side effects of Melanotan 2?

A: In the small clinical studies: nausea (severe in about one in eight men in the erection trials), yawning and stretching, flushing, fatigue, spontaneous erections and reduced appetite. In published case reports: eruptive and changing moles, melanoma, priapism, rhabdomyolysis with kidney injury, a kidney infarction and posterior reversible encephalopathy syndrome.

Q: What is the difference between Melanotan 1, Melanotan 2 and PT-141?

A: All three came from the same University of Arizona research program. Melanotan 1 is a more pigment-focused analogue that became the approved drug afamelanotide (Scenesse) for erythropoietic protoporphyria. Melanotan 2 is a smaller, more potent and less selective cyclic analogue that was never approved. PT-141 is an MT-2 analogue developed for sexual function that became the approved drug bremelanotide (Vyleesi).

Q: Is Melanotan 2 nasal spray safer than injections?

A: There is no evidence that it is. No regulator has approved any form, and a 2025 UK case report described a mucosal melanoma of the mouth in a young woman who had used an MT-2 nasal spray for tanning. Changing the route does not change the receptor effects or the unregulated manufacturing.

Related Guides

Sources

  • Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. PubMed 8637402
  • Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. PubMed 9679884
  • Wessells H, Gralnek D, Dorr R, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000;56(4):641-646. PubMed 11018622
  • Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-S79. PubMed 11035391
  • Dorr RT, Ertl G, Levine N, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol. 2004;140(7):827-835. PubMed 15262693
  • Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005;26(10):1687-1689. PubMed 15996790
  • Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. PubMed 16412534
  • Ramez M, Mostafa MM, Mohamed H, et al. Peptides for male sexual dysfunction: a systematic review of emerging evidence. J Sex Med. 2026;23(12):qdag338. PubMed 43002584
  • Cardones AR, Grichnik JM. alpha-Melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol. 2009;145(4):441-444. PubMed 19380666
  • Schulze F, Erdmann H, Hardkop LH, et al. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. Eur J Dermatol. 2014;24(1):107-109. PubMed 24334249
  • Melanotan case series from national journals: Ir Med J 2013 (PubMed 23914578), Actas Dermosifiliogr 2012 (PubMed 22425244), Ugeskr Laeger 2011 (PubMed 21453640), Lakartidningen 2013 (PubMed 23451671).
  • Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975-980. PubMed 28266027
  • Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):34-36. PubMed 24355990
  • Yassin Alsabbagh A, Bhujel N, Singh RP. Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? Int J Oral Maxillofac Surg. 2025;54(9):806-808. PubMed 40210573
  • Vadner DJ, Smith S. Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use. JAAD Case Rep. 2026;73:111-114. PubMed 42328529
  • Devlin J, Pomerleau A, Foote J. Melanotan II overdose associated with priapism. Clin Toxicol. 2013;51(4):383. PubMed 23537392
  • Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep. 2019;12(2):e227644. PubMed 30796078
  • Mallory CW, Lopategui DM, Cordon BH. Melanotan tanning injection: a rare cause of priapism. Sex Med. 2021;9(1):100298. PubMed 33460908
  • Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol. 2012;50(10):1169-1173. PubMed 23121206
  • Kaski D, Stafford N, Mehta A, et al. Melanotan and the posterior reversible encephalopathy syndrome. Ann Intern Med. 2013;158(9):707-708. PubMed 23648958
  • Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020;9(2):159-161. PubMed 31953620
  • Mullins ME, Pentecost G, Li JL. Tachycardia and rhabdomyolysis after use of melanotan and an uncommon synthetic cannabinoid receptor agonist. Am J Emerg Med. 2026;111:123-126. PubMed 42981758
  • Breindahl T, Evans-Brown M, Hindersson P, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015;7(2):164-172. PubMed 24771717
  • Sidhu AS, Konig DJ, Yu-Corpuz BX, Corpuz GS. Unregulated melanotan use promoted via social media: emerging dermatologic and public health risks. Int J Dermatol. 2026;65(6):1343-1344. PubMed 41559011
  • Affleck A. Consider underlying body dysmorphic disorder in users of melanotan. Br J Dermatol. 2010;162(2):459-460. PubMed 19919633
  • FDA. Certain bulk drug substances for use in compounding that may present significant safety risks, "nominated but withdrawn" table, Melanotan II entry. Content current as of April 22, 2026; read November 19, 2026.
  • FDA. Bulk drug substances used in compounding under section 503A, interim policy categories, content current as of May 14, 2026.
  • FDA. Import Alert 66-41, detention without physical examination of unapproved new drugs, Melanotan (I and II) entries.
  • FDA. Drugs@FDA records: Scenesse (afamelanotide), NDA 210797, approved October 8, 2019; Vyleesi (bremelanotide), NDA 210557, approved June 21, 2019; Imcivree (setmelanotide), NDA 213793, approved November 25, 2020.
  • HHS. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, Federal Register, October 30, 2026, Appendix A.
  • ClinicalTrials.gov. NCT07437560: Melanotan II as an adjunct to NB-UVB phototherapy in stable nonsegmental vitiligo (phase 2, recruiting). Searched for "melanotan" on November 19, 2026; this was the only registered study.

This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.

For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.

Share this article

Track Your Peptide Protocols

Use PeptIQ to log injections and vial supply, use peptiq.io calculators for math on the web, and keep protocols organized.

Stay ahead of the peptide conversation

Weekly-ish notes on new research, wiki trends, and practical tracking tips. No spam — unsubscribe anytime.

Educational updates only — not medical advice. Privacy